0001104659-22-004147.txt : 20220113 0001104659-22-004147.hdr.sgml : 20220113 20220113210026 ACCESSION NUMBER: 0001104659-22-004147 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220112 FILED AS OF DATE: 20220113 DATE AS OF CHANGE: 20220113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rawcliffe Adrian CENTRAL INDEX KEY: 0001555851 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37368 FILM NUMBER: 22530272 MAIL ADDRESS: STREET 1: 440 SOUTH BROAD STREET, UNIT 1906 CITY: PHILADELPHIA STATE: PA ZIP: 19146 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptimmune Therapeutics PLC CENTRAL INDEX KEY: 0001621227 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX BUSINESS PHONE: 44 1235 430000 MAIL ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX FORMER COMPANY: FORMER CONFORMED NAME: Adaptimmune Ltd DATE OF NAME CHANGE: 20141001 4 1 tm221700-5_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-01-12 0 0001621227 Adaptimmune Therapeutics PLC ADAP 0001555851 Rawcliffe Adrian C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK ABINGDON X0 OX14 4RX UNITED KINGDOM 1 1 0 0 Chief Executive Officer Option to purchase Ordinary Shares 0.60 2022-01-12 4 A 0 4690224 0 A 2032-01-12 Ordinary Shares 4690224 4690224 D Option to purchase Ordinary Shares 0.0014 2022-01-12 4 A 0 1047480 0 A Ordinary Shares 1047480 1047480 D The exercise price was converted from GBP0.44 based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount. Exercisable as to 1,172,556 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 97,818 Ordinary Shares on January 12, 2026. The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount. Exercisable as to 261,870 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 261,870 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026. The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. /s/ Adrian George Rawcliffe 2022-01-13